NDAINJECTIONINJECTABLE
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DOCETAXEL (docetaxel) by Dr. Reddy's Laboratories is functions. Approved for breast cancer, non-small cell lung cancer, prostate cancer. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Docetaxel is a microtubule-stabilizing chemotherapy agent approved for breast cancer, non-small cell lung cancer, and prostate cancer. It works by binding to tubulin and promoting microtubule assembly while inhibiting disassembly, leading to mitosis inhibition. The drug is administered intravenously and remains a foundational taxane in oncology regimens.
Peak
Docetaxel is at peak lifecycle as a mature, widely-used chemotherapy with stable demand; commercial teams are focused on retention and cost management rather than growth expansion.
Mechanism of Action
functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…
Indications (3)
Worked on DOCETAXEL at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.